Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003688 · ClinicalTrials.gov registry record · Phase 2

Dactinomycin in Treating Patients With Persistent or Recurrent Gestational Trophoblastic Neoplasia

A Phase 2 study, sponsored by Gynecologic Oncology Group.

Completed
Registry status
Phase 2
Development phase

NCT00003688: Completed Phase 2 study, sponsored by Gynecologic Oncology Group.

NCT00003688 is a Phase 2 study that has completed, run by Gynecologic Oncology Group. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003688, a Phase 2 study, has completed, sponsored by Gynecologic Oncology Group.

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dactinomycin in treating patients who have persistent or recurrent gestational trophoblastic neoplasia.

Interventions

  • BIOLOGICAL dactinomycin

Trial Details

FieldValue
Start Date 1999-10
Phase Phase 2
Gynecologic Oncology Group

154 total trials

What the finished NCT00003688 record still lists

NCT00003688 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which dactinomycin is the first listed.

NCT00003688 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00003688 about?

NCT00003688 is a clinical study titled "Dactinomycin in Treating Patients With Persistent or Recurrent Gestational Trophoblastic Neoplasia". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dactinomycin in treating patients who have persistent or recurrent gestational trophoblastic neoplasia.

What is the current status of trial NCT00003688?

This trial is currently completed. It is a Phase 2 study. The study started on 1999-10.

What interventions are being tested in trial NCT00003688?

The interventions under investigation include: dactinomycin (BIOLOGICAL).

Who is sponsoring clinical trial NCT00003688?

This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00003688, the US trial registry maintained by the National Library of Medicine. NCT00003688 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.